Prab: CSV import

2025-02-17T01:52:00Z

CSV import

← Older revision		Revision as of 01:52, 17 February 2025
Line 20:		Line 20:
	{{aminoglycosides}}		{{aminoglycosides}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Tobramycin.svg
			File:Tobramycin_1lc4.png
			</gallery>

Prab: Created page with " {{intro}} tobramycin is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial ..."

2019-04-21T20:36:01Z

Created page with " {{intro}} tobramycin is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial ..."

New page

{{intro}}
[[tobramycin]] is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe [[bacteria]]l [[infections]] due to sensitive organisms.

{{livtox}}
Despite its wide use, [[tobramycin]] has rarely been linked to instances of clinically apparent liver injury.

{{moa}}
[[tobramycin]] (toe" bra mye' sin) is a semisynthetic aminoglycoside, similar in spectrum of activity to [[gentamicin]], that is widely used for severe [[bacteria]]l [[infections]] caused by sensitive agents, primarily aerobic gram negative [[bacteria]]. Like other aminoglycosides, [[tobramycin]] is thought to act by binding to [[bacteria]]l ribosomes and inhibiting protein synthesis. Nevertheless, [[tobramycin]] is considered bacteriocidal as well as bacteriostatic. [[tobramycin]] and other aminoglycosides are typically used in combination with a penicillin or cephalosporin for treatment of severe [[infections]] with [[E.Coli]], Staphylococcus aureus, Enterobacter, Klebsiella, Serratia, Pseudomonas aeruginosa, and other gram negative [[bacteria]] resistant to less toxic antibiotics.

{{use}}
[[Tobramycin]] is most commonly used for septicemia, [[bacteria]]l endocarditis, peritonitis, meningitis, pelvic inflammatory disease and pneumonia.

{fda}}
[[Tobramycin]] was approved for use in the United States in 1980 and is available in multiple generic forms in parenteral formulations; typical adult doses are 3 mg/kg per day im or iv, usually in three divided doses, often after an initial loading dose. The dose of [[tobramycin]] must be modified based upon renal function and monitoring of drug levels is advisable. Pediatric formulations, nebulizer solutions for inhalation, and topical formulations for ophthalmologic use are also available.

{{se}}
Common side effects include dizziness, headache, confusion, nausea and skin rash. Important, dose related adverse effects include oto- and nephrotoxicity, which are shared by all aminoglycosides.

{{aminoglycosides}}
{{coststubd}}

Tobramycin - Revision history

Prab: CSV import

Prab: Created page with " {{intro}} tobramycin is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial ..."